Clinical trials: Moles
Brain Neoplasms, Melanoma
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
The goal of this clinical research study is to find the highest safe dose of lomustine (CCNU, CeeNUTM) that can be given with temozolomide (TemodarTM) and thalidomide (ThalomidTM) in the treatment of metastatic melanoma that has…
- Trial name
- NCT00527657
- Testing
- Lomustine, Temozolomide, Thalidomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic…
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01217411
- Testing
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with uveal melanoma that has spread to other places in the body (metastatic).
- Trial name
- NCT01585194
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: Phase I trial to study the effectiveness of boron neuron capture therapy in treating patients with stage III…
- Trial name
- NCT00002781
- Testing
- boronophenylalanine-fructose complex
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Beth Israel Deaconess Medical Center
Melanoma
Melanomas Excised in Primary Care vs Secondary Care Excision
Melanoma is the most dangerous skin cancer and is becoming commoner, largely due to increased foreign holidays and use of sun-beds. Melanoma usually begins as a new or changing mole.
- Trial name
- MelEx (NCT03169036)
- Volunteers
- 9,367 people
- Sponsor
- University of Aberdeen
Melanoma, Unsatisfied Needs
Holistic Needs Assessments in Patients With Melanoma
This study will assess whether a needs assessment/management intervention for patients with malignant melanoma is achievable, reasonable, realistic and of value to patients with malignant melanoma and health professionals…
- Trial name
- NCT06189261
- Testing
- Holistic needs assessment based on the use of patient-reported outcome measures
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Surrey
Melanoma, Merkel Cell Carcinoma
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT03901573
- Testing
- NT-I7, atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- NeoImmuneTech
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain
7T MRI Scan for the Early Detection of Melanoma Brain Metastases
This clinical trial studies the use of 7-Tesla (7T) magnetic resonance imaging (MRI) in detecting melanoma that has spread to the brain (melanoma brain metastases).
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04941430
- Testing
- Magnetic Resonance Imaging using 7 Tesla MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Thyroid Cancer, Breast Cancer
The Incidence of Breast and Other Cancers Among Female Flight Attendants
Flight attendants may be at an increased risk of breast and other cancers due to work-place exposures including cosmic radiation and circadian rhythm disruption form traveling across multiple time zones.
- Conditions
- Thyroid Cancer, Breast Cancer, Non-Melanoma Skin Cancer, Melanoma
- Trial name
- NCT00342407
- Where
- United States
- Volunteers
- 6,093 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Malignant Melanoma
A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
It is not known whether radiological assessments during follow up after surgery for high risk melanoma improve survival. Since radiological examinations are resource demanding, could inflict worry and cause irradiation exposure…
- Trial name
- TRIM (NCT03116412)
- Testing
- CT or PET scans
- Where
- 20 sites in Sweden
- Volunteers
- 1,300 people
- Sponsor
- Uppsala University
Metastatic Uveal Melanoma
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma.
- Trial name
- NCT06121180
- Testing
- ZIV-Aflibercept, Cemiplimab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic Proliferation
Skin melanoma is a common form of skin cancer. Its diagnosis is usually clinically suspected and then affirmed by histopathological examination.
- Trial name
- ANTIPRAME (NCT05089188)
- Testing
- Immunomarkers
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Strasbourg, France
Macular Edema, Cystoid Macular Edema
Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex) and compare it with safety and efficacy of intravitreal bevacizumab in eyes with macular edema after plaque radiotherapy of uveal melanoma.
- Conditions
- Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy
- Trial name
- NCT01471054
- Testing
- Ozurdex, Bevacizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Arman Mashayekhi
Metastatic Melanoma
Safety of ADU-1604 in Adults With Metastatic Melanoma
This study is a first-in-human, open-label, multicenter, dose-escalation study designed to evaluate the safety, PK, and PD of ADU-1604 and explore initial clinical activity in adults with metastatic melanoma.
- Trial name
- NCT03674502
- Testing
- ADU-1604
- Where
- 5 sites in France, Spain
- Volunteers
- 4 people
- Sponsor
- Aduro Biotech, Inc.
Melanoma, Lung Cancer
SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
Immune-related adverse events (irAEs) can be different in their onset, kinetics and presentation but unlike chemotherapy are seldom predictable.
- Trial name
- IRMA (NCT04929353)
- Testing
- Systematic symptom assessment
- Where
- Italy
- Volunteers
- 280 people
- Sponsor
- University Of Perugia
Melanoma (Skin)
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
The goal of this study is to observe metabolic features associated with human melanoma tumors.
- Trial name
- NCT06400550
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Texas Southwestern Medical Center
Melanoma (Skin Cancer)
Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma
A phase II double-blind placebo-controlled randomized trial. Patients with a clinical suspicion of a thick primary melanoma without clinical suspicion or evidence of lymph-node engagement will undergo a 3 mm punch biopsy to…
- Trial name
- NEOPRIME (NCT07349303)
- Testing
- Pembrolizumab
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Vastra Gotaland Region
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Axitinib + Ipilimumab in Advanced Melanoma
The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.
- Trial name
- NCT04996823
- Testing
- Ipilimumab, Axitinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute